May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Cationic Oil-in-Water Emulsion as an Improved Cyclosporine Ocular Vehicle for Vernal Keratoconjuctivitis Sicca (VKC)
Author Affiliations & Notes
  • G. Lambert
    Novagali Pharma SA, Evry, France
  • L. Rabinovich-Guilatt
    Novagali Pharma SA, Evry, France
  • Footnotes
    Commercial Relationships G. Lambert, Novagali, E; L. Rabinovich-Guilatt, Novagali, E.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 2301. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      G. Lambert, L. Rabinovich-Guilatt; Cationic Oil-in-Water Emulsion as an Improved Cyclosporine Ocular Vehicle for Vernal Keratoconjuctivitis Sicca (VKC). Invest. Ophthalmol. Vis. Sci. 2007;48(13):2301.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract 
 
Purpose:
 

To compare corneal and conjunctiva pharmacokinetics of CsA in rabbits following topical administration in olive oil or cationic oil-in-water emulsion.

 
Methods:
 

Rabbits received a single instillation of 2% CsA in olive oil or 0.1% CsA in emulsion. Corneal, conjunctival and whole blood CsA levels were analysed by HPLC-MS. Experimental work was performed at Iris Pharma (La Gaude, France).

 
Results:
 

Figure 1: Corneal (A) and conjunctival (B) CsA concentrations (ng/g) after instillation of 50 µL of 2% CsA in olive oil or 0.1% CsA in emulsion.Although the administered dose was 20-fold less important in the emulsion (0.05 mg) compared to the oil group (1 mg), the resultant corneal AUC1-24 (area-under-the curve between 1 and 24hr) was only 1.8-fold less (48970 and 27249 ng/g*hr respectively). After normalization by the administered dose, this results in an 11-fold improvement in ocular bioavailability.Quantifiable whole blood levels were identified only in one animal of the oil group, at the first time-point (2 ng/ml).  

 
Conclusions:
 

Formulation of CsA in a cationic emulsion (NOVA22007) results in significantly (11-fold) improved corneal and conjunctival delivery compared to administration in oil, allowing a lower dose and reducing potential systemic passage. Moreover, the emulsion is expected to have a much better tolerability than the pure oil. A phase III clinical trial is currently ongoing in Europe and Mediterranean countries.

 
Keywords: cyclosporine • keratitis • conjunctivitis 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×